APA (7th ed.) Citation

Pivot, X., Romieu, G., Debled, M., Pierga, J., Kerbrat, P., Bachelot, T., . . . Kramar, A. (2013). 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): A randomised phase 3 trial. The lancet oncology, 14(8), 741-748. https://doi.org/10.1016/S1470-2045(13)70225-0

Chicago Style (17th ed.) Citation

Pivot, Xavier, et al. "6 Months Versus 12 Months of Adjuvant Trastuzumab for Patients with HER2-positive Early Breast Cancer (PHARE): A Randomised Phase 3 Trial." The Lancet Oncology 14, no. 8 (2013): 741-748. https://doi.org/10.1016/S1470-2045(13)70225-0.

MLA (9th ed.) Citation

Pivot, Xavier, et al. "6 Months Versus 12 Months of Adjuvant Trastuzumab for Patients with HER2-positive Early Breast Cancer (PHARE): A Randomised Phase 3 Trial." The Lancet Oncology, vol. 14, no. 8, 2013, pp. 741-748, https://doi.org/10.1016/S1470-2045(13)70225-0.